Mirvetuximab soravtansine

Mirvetuximab soravtansine-gynx (IMGN853) is a folate receptor alpha (FRα)-directed antibody-drug conjugate (ADC) consisting of three components: 1) an anti-FRα monoclonal antibody of IgG1 subtype 2) the small molecule anti-tubulin agent DM4 (a maytansine derivative) and 3) a linker, sulfo-SPDB (1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid) that covalently attaches DM4 to the mirvetuximab antibody. Mirvetuximab soravtansine-gynx has an approximate molecular weight of 150 kDa. The DAR is n = ~3.4. Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage. This product is for research use only.

Product Details
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Mirvetuximab (Anti- FOLR1)
ADC cytotoxin (drug)	DM4
Immunogen	folate receptor α (FRα)
DAR (Drug to Antibody Ratio)	~3.4
Purity	99%
Molecular Weight	150kDa
Protein Concentration	10mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	97.6 μL in 10mM Histidine pH=5.5